On Aug. 15, 2022, the U.S. Department of Health and Human Services announced that was making up to 442,000 doses of the JYNNEOS vaccine available for states and jurisdictions to order under an accelerated Phase 3 of the National Vaccine Strategy (NVS) to combat the current monkeypox outbreak.

Under the FDA EUA for JYNNEOS, the vaccine may be injected intradermally (in the upper skin layer) for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection ﾖ a change that increases doses by up to five-fold.